News

The company said that proceeds from the financing will be used to reduce the debt load of the company and to fund its marketing program in North America

RxElite has acquired the physical facilities, the intellectual property and patents of FineTech and has retained all FineTech employees. FineTech’s scientists conduct proprietary R&D and manufacture complex active

The company said that the Xcelerant hydro delivery system is designed to aid navigation of the device through tight and tortuous arteries by reducing friction with the artery

The defendants named in the lawsuits include Barr Laboratories, Cobalt Laboratories, Lupin, Orchid Chemicals & Pharmaceuticals, Teva Pharmaceuticals USA, Upsher-Smith Laboratories, Wockhardt and related companies and subsidiaries thereof.

Under the terms of the agreement, Jerini will use its peptides-to-drugs (P2D) technology platform to identify and develop a specific binding molecule for protein purification, which potentially offers

This ongoing trial has been designed to assess the efficacy of TG4010 (MVA-MUC1-IL2) in combination with cisplatin and gemcitabine compared to the chemotherapy regimen alone. The patients in

The FDA’s revised action date for methylnaltrexone is now April 30, 2008. The FDA, in its review of this new drug application (NDA), requested the results from a

The acceptance of the new drug application (NDA), which was submitted on October 31, 2007, means the FDA has made an initial determination that the NDA is sufficiently

The company said that the approval of the general hemostasis in surgery indication is based on the submission of clinical data related to three pivotal studies conducted in